Quadrant Capital Group’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-298
| Closed | -$10.8K | – | 2300 |
|
|
2025
Q1 | $10.8K | Buy |
298
+11
| +4% | +$398 | ﹤0.01% | 2206 |
|
|
2024
Q4 | $12.1K | Hold |
287
| – | – | ﹤0.01% | 2068 |
|
|
2024
Q3 | $15.9K | Hold |
287
| – | – | ﹤0.01% | 1984 |
|
|
2024
Q2 | $11.8K | Sell |
287
-110
| -28% | -$4.52K | ﹤0.01% | 2063 |
|
|
2024
Q1 | $18.5K | Buy |
397
+80
| +25% | +$3.74K | ﹤0.01% | 1880 |
|
|
2023
Q4 | $15.2K | Sell |
317
-94
| -23% | -$4.5K | ﹤0.01% | 1917 |
|
|
2023
Q3 | $14.7K | Sell |
411
-756
| -65% | -$27K | ﹤0.01% | 1839 |
|
|
2023
Q2 | $53.8K | Sell |
1,167
-163
| -12% | -$7.52K | 0.01% | 1223 |
|
|
2023
Q1 | $53.3K | Buy |
1,330
+406
| +44% | +$16.3K | 0.01% | 1203 |
|
|
2022
Q4 | $42.8K | Buy |
924
+487
| +111% | +$22.6K | ﹤0.01% | 1253 |
|
|
2022
Q3 | $18K | Buy |
437
+266
| +156% | +$11K | ﹤0.01% | 1615 |
|
|
2022
Q2 | $10K | Buy |
171
+149
| +677% | +$8.71K | ﹤0.01% | 1672 |
|
|
2022
Q1 | $1K | Sell |
22
-37
| -63% | -$1.68K | ﹤0.01% | 2365 |
|
|
2021
Q4 | $5K | Buy |
59
+34
| +136% | +$2.88K | ﹤0.01% | 1892 |
|
|
2021
Q3 | $2K | Buy |
25
+22
| +733% | +$1.76K | ﹤0.01% | 2183 |
|
|
2021
Q2 | $0 | Sell |
3
-54
| -95% | – | ﹤0.01% | 2527 |
|
|
2021
Q1 | $6K | Buy |
+57
| New | +$6K | ﹤0.01% | 1736 |
|
|
2020
Q2 | – | Sell |
-4
| Closed | – | – | 2362 |
|
|
2020
Q1 | $0 | Buy |
+4
| New | – | ﹤0.01% | 2237 |
|
|
2019
Q4 | – | Sell |
-136
| Closed | -$5K | – | 2475 |
|
|
2019
Q3 | $5K | Buy |
+136
| New | +$5K | ﹤0.01% | 1928 |
|
|
2016
Q2 | – | Sell |
-94
| Closed | -$5K | – | 2059 |
|
|
2016
Q1 | $5K | Buy |
94
+39
| +71% | +$2.07K | ﹤0.01% | 1171 |
|
|
2015
Q4 | $6K | Buy |
+55
| New | +$6K | ﹤0.01% | 1005 |
|